Table 1:

Patient characteristics

	All patients (N=112)
Age, years	60 (48–66)
Sex
Female	27 (24%)
Male	85 (76%)
Race
White	90 (80%)
African	18 (16%)
Asian	1 (<1%)
Unknown	3 (3%)
Comorbidities*
Hypertension	60 (54%)
Diabetes	18 (16%)
Elevated cholesterol	24 (21%)
Deep vein thrombosis or pulmonary embolism	11 (10%)
Atrial fibrillation	10 (9%)
ECOG performance status
0	23 (20%)
1	59 (53%)
2–3	11 (10%)
Unknown	19 (17%)
Stage at diagnosis
I–III	54 (48%)
IV	58 (52%)
Previous nephrectomy
No	26 (23%)
Radical	73 (65%)
Partial	13 (12%)
Cytoreductive intent	35 (41%)
Histology
Papillary	66 (59%)
Xp11·2 translocation	17 (15%)
Unclassified	15 (13%)
Chromophobe	10 (9%)
Collecting duct	4 (4%)
Sarcomatoid component
Yes	30 (27%)
<20%	7 (23%)
20–70%	8 (27%)
>70%	4 (13%)
Unknown	11 (37%)
No	51 (46%)
Unknown	31 (28%)
Necrosis component
Yes	38 (34%)
No	25 (22%)
Unknown	49 (44%)
Fuhrman grade
1–2	5 (4%)
3	35 (31%)
4	31 (28%)
Unknown	41 (37%)
IMDC risk group
Favourable	9 (8%)
Intermediate	71 (63%)
Poor	29 (26%)
Unknown	3 (3%)
Sites of metastasest†
Lymph nodes	95 (85%)
Lung	66 (59%)
Bone	49 (44%)
Liver	42 (38%)
Brain	6 (5%)
Number of previous systemic therapies
0	22 (20%)
1	31 (28%)
2	32 (29%)
≥3	27 (24%)
Type of previous systemic treatment
Tyrosine kinase inhibitor	39 (35%)
Immunotherapy	12 (11%)
Tyrosine kinase inhibitor and immunotherapy	36 (32%)
Other	3 (3%)
None	22 (20%)

Data are median (IQR) or n (%). ECOG=Eastern Cooperative Oncology Group. IMDC=International Metastatic Renal Cell Carcinoma Database Consortium.

^*The five most frequent comorbidities are shown. More than one comorbidity per patient might be included if present.

^†Patients might have had more than one metastatic site.